Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GRI Bio ( (GRI) ) has provided an update.
On July 31, 2025, GRI Bio announced interim biomarker data from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis, showing positive impacts on fibrogenesis, fibrolysis, and potential repair response. The Independent Data Monitoring Committee found no safety concerns and recommended continuing the study, which is fully enrolled and on track for topline data in Q3 2025. The study aims to address the limitations of current IPF treatments, which have significant side effects and limited efficacy.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. The company targets Natural Killer T (NKT) cells to interrupt disease progression and restore immune system balance. Their lead program, GRI-0621, is an oral therapeutic for idiopathic pulmonary fibrosis, and they are also developing treatments for systemic lupus erythematosus.
Average Trading Volume: 244,214
Technical Sentiment Signal: Sell
Current Market Cap: $4.89M
See more data about GRI stock on TipRanks’ Stock Analysis page.